Disease-specific quality of life in multiple sclerosis: The effect of disease modifying treatment

Multiple Sclerosis

Volumn 12, Issue 6, 2006, Pages 808-813

  Lily, Oliver ^a   McFadden, E ^a   Hensor, E ^a   Johnson, M ^a   Ford, H ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Beta interferon; Expanded Disability Status Scores; Glatiramer acetate; Leeds MS Quality of Life scale; Multiple sclerosis; Quality of life

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RATING SCALE; RECURRENCE RISK; SELF REPORT; TREATMENT WITHDRAWAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; DISABILITY EVALUATION; FEMALE; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT DROPOUTS; PEPTIDES; QUALITY OF LIFE; REGRESSION ANALYSIS;

EID: 33846287988     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070946     Document Type: Article

References (28)

1. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-76.
5. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a In MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504.
6. Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003; 24: S265-67.
7. National Institute of Clinical Excellence. Beta-interferon and glatiramer acetate for the treatment of multiple sclerosis. 2002. Retrieved from www.nice.org.uk
8. Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. Health Service Circular, 2002.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
10. Noseworthy JH. Clinical scoring methods for multiple sclerosis. Ann Neurol 1994; 36: S80-85.
11. Thompson AJ, Hobart JC. Multiple sclerosis: assessment of disability and disability scales. J Neurol 1998; 245: 189-96.
12. Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; 62: 601-606.
13. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 1990; 40: 971-75.
14. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF et al. IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87.
15. Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis: influence of interferon-beta 1a (Avonex) treatment. Mult Scler 2002; 8: 377-81.
16. Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003; 216: 113-18.
17. Isaksson AK, Ahlstrom G, Gunnarsson LG. Quality of life and impairment in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 64-69.
18. Nicholl CR, Lincoln NB, Francis VM, Stephan TF. Assessing quality of life in people with multiple sclerosis. Disabil Rehabil 2001; 23: 597-603.
19. Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001; 15: 247-58.
20. Ford HL, Gerry E, Johnson MH, Tennant A. Health status and quality of life of people with multiple sclerosis. Disabil Rehabil 200; 23: 516-21.
21. Ford HL, Eyres S, Tennant A. Measuring change in multiple sclerosis: responsiveness of three outcome measures. J Neurol Sci 2001; 187: S456.
22. Greenhalgh J, Ford H, Long AF, Hurst K. The MS symptom and impact diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis. JNNP 2004; 75: 577-582.
23. Sullivan LM, D'Agostino RB Sr. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials. Stat Med 2003; 22: 1317-34.
24. Walters SJ, Campbell MJ, Lall R. Design and analysis of trials with quality of life as an outcome: a practical guide. J Biopharm Stat 2001; 11: 155-76.
25. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005; 4: 556-66.
26. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001; (4): CD002002.
27. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48: 885-92.
28. White AT, Petajan JH. Physiological measures of therapeutic response to interferon beta-1a treatment in remitting-relapsing MS. Clin Neurophysiol 2004; 115: 2364-71.